The Food and Drug Administration (FDA) has shown signs of flexibility in its approach to clinical trials for rare disease therapies, according to industry executives and recent trial experiences reported on April 13. CERo Therapeutics, a Bay Area biotechnology company, received FDA approval within 30 days to amend its Phase 1 trial of CER-1236—an autologous T cell therapy originally focused on acute myeloid leukemia—to include patients with myelodysplastic syndrome after an unexpectedly positive patient response.
This development is significant as the FDA faces criticism from politicians, patient advocates, and biotech leaders for what they describe as inconsistent regulatory clarity, especially concerning rare diseases. A coalition recently urged the Trump administration to "restore regulatory clarity" as the agency considers new leadership for the Center for Biologics Evaluation and Research.
Robert Sikorski, chief medical officer at CERo Therapeutics, said that his team was able to move quickly into a new set of patient populations without downtime due to responsive collaboration from the FDA. “We hadn’t expected that,” Sikorski told BioSpace. He added that early-stage clinical trial staff at the agency have been constructive overall: “I have not observed a lack of flexibility in recent early-stage trials.”
Other companies have also reported positive experiences. Rezolute received permission from the FDA in August 2025 to shift its Phase 3 trial design for ersodetug—a treatment targeting tumor hyperinsulinism—from a randomized controlled study to a smaller single-arm format. The agency has also issued draft guidance encouraging innovative approaches such as externally controlled or single-arm studies when developing cell and gene therapies for severe conditions affecting small populations.
Despite these examples of adaptability, some companies remain frustrated by reversals or changes in guidance during late-stage reviews or product assessments. Regulatory experts say this is not necessarily inappropriate; Holly Fernandez Lynch from the University of Pennsylvania School of Medicine noted that future FDA leaders are not bound by previous decisions: “Just because the FDA said something doesn’t mean that future FDAs should not be able to say, ‘That was wrong.’”
The FDA continues introducing new programs aimed at expediting drug development and improving communication with sponsors. These include Breakthrough Therapy and Fast Track designations, along with newer initiatives like the Commissioner’s National Priority Voucher program launched in June 2025 and a proposed "clinical trial notification pathway" intended to simplify early-phase clinical research entry.
Harpreet Singh, chief medical officer at Precision for Medicine and former oncology regulator at the FDA, recommends frequent engagement between sponsors and regulators: “From the leadership we are seeing more enthusiasm...to engage directly with industry.” Singh advises companies seeking approval: “[It’s] that old adage; engage early and often.”
Looking ahead, further changes may come if proposals outlined in upcoming federal budgets are enacted—potentially expanding funding by over $200 million while launching additional programs designed to expedite approvals.
